VPHIF (Valeo Pharma) EBITDA Margin %: -28.50% (As of Jul. 2024)

What is Valeo Pharma EBITDA Margin %?

Valeo Pharma VPHIF -99.00% 12 EBITDA Margin % is -28.50% as of Jul. 2024. GuruFocus rates VPHIF with a GF Score™ of 12/100.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Valeo Pharma's EBITDA for the three months ended in Jul. 2024 was $-2.62 Mil. Valeo Pharma's Revenue for the three months ended in Jul. 2024 was $9.19 Mil. Therefore, Valeo Pharma's EBITDA margin for the quarter that ended in Jul. 2024 was -28.50%.

Valeo Pharma (OTCPK:VPHIF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Valeo Pharma EBITDA Margin % Related Terms

Valeo Pharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Valeo Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valeo Pharma EBITDA Margin % Chart

Valeo Pharma Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

EBITDA Margin %

Get a 7-Day Free Trial

-51.23

-50.06

-89.51

-68.63

-21.13

Valeo Pharma Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
EBITDA Margin %	Get a 7-Day Free Trial															-12.46	-36.15	-17.83	-23.57	-28.50

VPHIF vs ZTS: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Valeo Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valeo Pharma EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Valeo Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Valeo Pharma's EBITDA Margin % falls into.

Save Embed

12GF Score

Valeo Pharma Inc VPHIF

EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Valeo Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Valeo Pharma's EBITDA Margin % for the fiscal year that ended in Oct. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Oct. 2023 )	/	Revenue (A: Oct. 2023 )
	=	-8.308	/	39.316
	=	-21.13 %

Valeo Pharma's EBITDA Margin % for the quarter that ended in Jul. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jul. 2024 )	/	Revenue (Q: Jul. 2024 )
	=	-2.619	/	9.188
	=	-28.50 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of -28.50% mean?

Valeo Pharma (VPHIF) has a EBITDA Margin % of -28.50% as of Jul. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Valeo Pharma and its competitors.

Is Valeo Pharma's EBITDA Margin % too high?

Valeo Pharma's current EBITDA Margin % is -28.50%. Overall, Valeo Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Valeo Pharma's EBITDA Margin % compare to ZTS?

Valeo Pharma's EBITDA Margin % of -28.50% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Drug Manufacturers company?

The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Valeo Pharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valeo Pharma's current EBITDA Margin % is -28.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Valeo Pharma stock overvalued right now?

Valeo Pharma (VPHIF) has a current EBITDA Margin % of -28.50%. The current EBITDA Margin % is -28.50%. Valeo Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Valeo Pharma (VPHIF), the current EBITDA Margin % is -28.50% as of Jul. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Valeo Pharma Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies XCNQ:CANN TSX:XLY XCNQ:XTRX TSXV:MPH XCNQ:BAMM TSX:CTX NEOE:TILT XCNQ:MVMD XCNQ:VIN XCNQ:PWR ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692

Address 16667, Hymus Boulevard, Kirkland, QC, CAN, H9H 4R9

Website https://www.valeopharma.com

Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and hospital specialty products. Its product portfolio includes medicines for Respiratory/Allergy, Ophthalmology, Neurology, and Oncology.

12GF Score

Get the complete analysis for VPHIF

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View VPHIF Analysis

See EBITDA Margin % data for all stocks →